HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rosewich, H Articles by Gärtner, J Search for Related Content PubMed PubMed Citation Articles by Rosewich, H Articles by Gärtner, J Topic Collections JMG Online mutation reports

Genetic and clinical aspects of Zellweger spectrum patients with PEX1 mutations

Department of Paediatrics and Paediatric Neurology, Georg August University, Göttingen, Germany

Correspondence to:
Dr Jutta Gärtner
Department of Paediatrics and Paediatric Neurology, Georg August University, Robert-Koch-Strasse 40, 37075 Göttingen, Germany; gaertnj{at}med.uni-goettingen.de] Objective: To analyse the PEX1 gene, the most common cause for peroxisome biogenesis disorders (PBD), in a consecutive series of patients with Zellweger spectrum.

Methods: Mutations were detected by different methods including SSCP analyses as a screening technique on the basis of genomic or cDNA, followed by direct sequencing of PCR fragments with an abnormal electrophoresis pattern.

Results: 33 patients were studied. Two common mutations, c.2528GA, G843D and c.2098_2098insT, I700YfsX42, accounted for over 80% of all abnormal PEX1 alleles, emphasising their diagnostic relevance. Most PEX1 mutations were distributed over the two AAA cassettes with the two functional protein domains, D1 and D2, and the highly conserved Walker motifs. Phenotypic severity of Zellweger spectrum in CG1 depended on the effect of the mutation on the PEX1 protein, peroxin 1. PEX1 mutations could be divided into two classes of genotype–phenotype correlation: class I mutations led to residual PEX1 protein levels and function and a milder phenotype; class II mutations almost abolished PEX1 protein levels and function, resulting in a severe phenotype. Compound heterozygote patients for a class I and class II mutation had an intermediate phenotype.

Conclusions: Molecular confirmation of the clinical and biochemical diagnosis will allow the prediction of the clinical course of disease in individual PBD cases.

Abbreviations: HGVS, Human Genome Variation Society; IRD, infantile Refsum disease; NSF, N-ethylmaleimide sensitive factor; NTD, N terminal domain; PBD, peroxisome biogenesis disorder; RCDP, rhizomelia chondrodysplasia punctata; VCP, valosin containing protein

Keywords: PEX1; peroxin; peroxisome biogenesis disorder; Zellweger syndrome